Metagenomi Inc. Faces Class Action Lawsuit for Misleading Statements
In a significant development for investors, a class action lawsuit has been initiated concerning Metagenomi Inc. (NASDAQ: MGX). This legal action is being led by Kirby McInerney LLP, a renowned law firm known for its efforts to advocate for investors' rights. The lawsuit has been filed in the U.S. District Court for the Northern District of California, aimed at those who purchased Metagenomi securities during a specific time frame.
Understanding the Lawsuit
The class action encompasses those investors who acquired Metagenomi securities between February 9, 2024, and May 1, 2024. The deadline for affected individuals to apply to become lead plaintiffs in the case is November 25, 2024. This timeline is critical for investors looking to assert their rights and potentially receive compensation stemming from this lawsuit.
Background of the Initial Public Offering
Metagenomi went public on February 12, 2024, and was able to sell approximately 6.25 million shares at a price of $15 each. However, this seemingly successful initial public offering (IPO) took a downward turn shortly after. On May 1, 2024, Metagenomi announced the termination of its collaboration with Moderna, a leading company in the vaccine industry.
Impact of the Collaboration Termination
This announcement greatly affected Metagenomi’s share price, leading to a substantial decline. Following the news, Metagenomi's stock dropped by $0.87, which is a significant 12.4% decrease, closing at $6.17 per share on May 2, 2024. Investors who believed in the company's long-term potential were left in a challenging position as the truth regarding the collaboration began to unfold.
Details of the Allegations
According to the lawsuit, the statements made by Metagenomi during its IPO registration were misleading or untruthful. The company portrayed itself as a robust player in the genetic medicines space, capitalizing on its supposed partnership with Moderna. However, as investors found out, this partnership was not intended to endure, raising questions about Metagenomi's transparency during its IPO.
Investors' Rights and Legal Support
For those who purchased shares or have pertinent information regarding Metagenomi’s IPO, it is crucial to seek assistance. Kirby McInerney LLP has extended an invitation for investors to reach out, promising support at no upfront cost. Interested parties can contact Thomas W. Elrod of the law firm to discuss their options or share information.
About Kirby McInerney LLP
Kirby McInerney LLP is based in New York and specializes in various areas of law, including securities, antitrust issues, and consumer litigation. The firm is recognized for its commitment to recovering funds for shareholders through securities litigation, having achieved total recoveries that amount to billions of dollars. Such a reputation underscores their dedication and capability to handle complex legal matters effectively.
Frequently Asked Questions
What is the class action lawsuit against Metagenomi about?
The class action lawsuit centers on misleading statements made by Metagenomi during its IPO, leading to investor losses following the termination of its collaboration with Moderna.
What actions should affected investors take?
Affected investors are encouraged to contact Kirby McInerney LLP to discuss their rights and potentially join the class action lawsuit.
What was the IPO price of Metagenomi's shares?
Metagenomi's shares were priced at $15 each during its initial public offering on February 12, 2024.
When did the collaboration with Moderna end?
The collaboration between Metagenomi and Moderna was announced to be terminated on May 1, 2024.
What type of law firm is Kirby McInerney LLP?
Kirby McInerney LLP is a plaintiffs' law firm that specializes in securities, antitrust, whistleblower, and consumer litigation, focusing on protecting investors' rights.
